Editas Medicine Inc

NASDAQ:EDIT  
11.02
+0.08 (+0.73%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)761.93M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$4.29 Million
Adjusted EPS-$0.81
See more estimates
10-Day MA$11.53
50-Day MA$15.68
200-Day MA$31.30
See more pivots

Editas Medicine Inc Stock, NASDAQ:EDIT

11 Hurley Street, 11 Hurley Street, Cambridge, Massachusetts 02141
United States of America
Phone: +1.617.401.9000
Number of Employees: 264

Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.